<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342404</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-536-B-THAL-002</org_study_id>
    <secondary_id>U1111-1202-7068</secondary_id>
    <secondary_id>2015-003225-33</secondary_id>
    <nct_id>NCT03342404</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia</brief_title>
  <acronym>BEYOND</acronym>
  <official_title>A Phase 2, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Non-Transfusion Dependent Beta (B)-Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, double-blind, randomized, placebo-controlled, multicenter study to&#xD;
      determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with&#xD;
      non-transfusion dependent beta (β)-thalassemia. The study is divided into the Screening&#xD;
      Period, Double-blind Treatment Period (DBTP) and Post-Treatment Follow-up Period (PTFP).&#xD;
&#xD;
      It is planned to randomize approximately 150 subjects at a 2:1 ratio of luspatercept versus&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is:&#xD;
&#xD;
      - To evaluate the effect of luspatercept in non-transfusion dependent β-thalassemia-patient&#xD;
      versus placebo on anemia, as measured by mean hemoglobin concentration in the absence of&#xD;
      transfusions over a continuous 12-week interval, from Week 13 to Week 24, compared to&#xD;
      baseline.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on β-thalassemia related symptoms,&#xD;
           as measured by non transfusion dependent β-thalassemia-patient reported outcome&#xD;
           (NTDT-PRO) over a continuous 12-week intervals (from Weeks 13 to 24 and from Weeks 37 to&#xD;
           48) compared to baseline.&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on functional and health-related&#xD;
           quality of life (QoL) as measured by Medical Outcomes Study 36-Item Short Form (SF-36)&#xD;
           and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaires&#xD;
&#xD;
        -  To evaluate the long-term effect of luspatercept versus placebo on anemia, as measured&#xD;
           by mean hemoglobin concentration in the absence of transfusions over a continuous&#xD;
           12-week interval from Week 37 to Week 48, compared to baseline&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on iron overload, as measured by&#xD;
           liver iron concentration (LIC) and iron chelation therapy (ICT) daily dose&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on iron overload, as measured by&#xD;
           serum ferritin&#xD;
&#xD;
        -  To evaluate the duration of erythroid response&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on physical activity measured by&#xD;
           6-minute walk test (6MWT)&#xD;
&#xD;
      Safety and Pharmacokinetics (PK) Objectives&#xD;
&#xD;
        -  To evaluate safety and tolerability of luspatercept, including immunogenicity&#xD;
&#xD;
        -  To evaluate population pharmacokinetics (PK) of luspatercept in subjects with β-&#xD;
           thalassemia&#xD;
&#xD;
      The exploratory objectives are:&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on measures of extra-medullary&#xD;
           hematopoietic (EMH) masses, bone mineral density, splenomegaly, pulmonary hypertension,&#xD;
           and leg ulcers, when present&#xD;
&#xD;
        -  To evaluate the effect of luspatercept versus placebo on the β-thalassemia severity as&#xD;
           measured by the NTDT severity score system&#xD;
&#xD;
        -  To examine the relationship of baseline and change in serum Growth Differentiation&#xD;
           Factor 11 (GDF11) and other related biomarkers with response to treatment with&#xD;
           luspatercept&#xD;
&#xD;
        -  To examine the effect of luspatercept on fetal hemoglobin (HbF)&#xD;
&#xD;
        -  To examine the effect of luspatercept on Health Resource Utilization (HRU)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Actual">September 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Erythroid Response (Week 13 to Week 24)</measure>
    <time_frame>From Week 13 to Week 24 of study treatment</time_frame>
    <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 13 to 24 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 13 to Week 24)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
    <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the T/W Domain Score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 13 to Week 24)</measure>
    <time_frame>From Week 13 to Week 24 of study treatment (over a continuous 12-week interval)</time_frame>
    <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Erythroid Response (Week 37 to Week 48)</measure>
    <time_frame>From Week 37 to Week 48 of study treatment</time_frame>
    <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 37 to 48 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
    <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 13 to Week 24 is compared to the FS score at baseline (last score available before start of study treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 13 to Week 24)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
    <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the SoB Domain Score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 37 to Week 48)</measure>
    <time_frame>From Week 37 to Week 48 of study treatment (over a continuous 12-week interval)</time_frame>
    <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
    <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 37 to Week 48 is compared to the FS score at baseline (last score available before start of study treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 37 to Week 48)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
    <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the T/W Domain Score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 37 to Week 48)</measure>
    <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
    <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the SoB Domain Score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</measure>
    <time_frame>From Week 13 to Week 24 of study treatment (over a continuous 12-week interval)</time_frame>
    <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</measure>
    <time_frame>From Week 37 to Week 48 of study treatment (over a continuous 12-week interval)</time_frame>
    <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of the Medical Outcomes Study 36-Item Short Form (SF-36)</measure>
    <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
    <description>The SF-36v2 is a 36-item generic PRO questionnaire used to assess patient-reported outcomes. The SF-36 yields scores for 8 domains of health: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH) as well as physical component summary (PCS) and mental component summary (MCS) scores.&#xD;
Scores from each of the 8 domains of health are first normalized based on US general population means, then aggregated and transformed (according to specific standardization formulas detailed in the Statistical Protocol Analysis), so that the scores from each of the 8 domains of health will contribute differently to the determination of PCS and MCS summary scores.&#xD;
PCS and MCS scores range from 0 to 100, with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement of Iron Overload</measure>
    <time_frame>Week 24 and Week 48 of study treatment</time_frame>
    <description>Iron overload was measured by Liver Iron Concentration (LIC) and Iron Chelation Therapy (ICT) daily dose.&#xD;
Improvement is defined as:&#xD;
For participants with baseline LIC ≥3 mg/g: ≥20% reduction in LIC or ≥ 33% decrease in ICT daily dose&#xD;
For participants with baseline LIC &lt;3 mg/g: no increase in LIC &gt;1 mg/g and not starting treatment with ICT, or no increase in ICT daily dose ≥ 33% (if on ICT at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Serum Ferritin</measure>
    <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
    <description>Baseline mean serum ferritin is calculated during the 24 weeks on or prior to dose 1 day 1. Post-baseline mean serum ferritin is calculated as mean of ferritin values during the last 24 weeks on or prior to the end date of the first 24 week or 48 week treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Liver Iron Concentration (LIC)</measure>
    <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
    <description>LIC was measured by Magnetic Resonance Imaging (MRI). Baseline is defined as the last value on or before the first dose of study drug is administered; Postbaseline is defined as the closest visit at Week 24 or Week 48.&#xD;
Participants with LIC value &gt;43 are not included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Transfusion-Free Over 24 Weeks</measure>
    <time_frame>From start of treatment to 24 weeks following start of treatment</time_frame>
    <description>Transfusion free is defined as the absence of any transfusion during Week 1-24 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 24 were not considered as transfusion free during Week 1-24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Transfusion-Free Over 48 Weeks</measure>
    <time_frame>From start of treatment to 48 weeks following start of treatment</time_frame>
    <description>Transfusion free is defined as the absence of any transfusion during Week 1-48 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 48 were not considered as transfusion free during Week 1-48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the Mean Hemoglobin Increase From Baseline ≥1.0 g/dL</measure>
    <time_frame>From first to last Hemoglobin measurement with increase from baseline ≥1.0 g/dL (up to approximately 20 months)</time_frame>
    <description>The duration of increase is defined as Last Day of mean hemoglobin increase by &gt;=1.0g/dL - First Day of increase +1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the 6-Minute Walk Test (6MWT) Distance</measure>
    <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
    <description>The 6MWT is typically used to objectively assess functional exercise capacity and response to medical interventions in patients with various moderate to severe diseases. Subjects are asked to walk as quickly as possible without running along a 30-meter corridor for six minutes, and the total distance covered during that time is measured.&#xD;
Baseline is defined as the last value on or before the first dose of study drug is administered. Postbaseline is defined as the closest visit at Week 24 or Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase From Baseline ≥1.5 g/dL in Mean Hemoglobin Values in the Absence of Transfusion</measure>
    <time_frame>From Week 13 to Week 24 of study treatment</time_frame>
    <description>Percentage of participants who have an increase from baseline ≥1.5 g/dL in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease From Baseline ≥ RD (= 1) in the Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score</measure>
    <time_frame>From Week 13 to Week 24 and from Week 37 to Week 48 of study treatment</time_frame>
    <description>The RD for the NTDT-PRO T/W domain score was defined as ≥ 1-point decrease (ie, RD = -1) from baseline over the time from Week 13 to Week 24 or from Week 37 to Week 48.&#xD;
Subjects with missing NTDT-PRO T/W scores at the indicated 12-week period are classified as non-responders in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>From first dose to 63 days after last dose (up to approximately 50 months)</time_frame>
    <description>Number of participants experiencing different types (any grade) of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug Antibody (ADA) Positive Test for Luspatercept</measure>
    <time_frame>From first dose and up to 2 years following last dose</time_frame>
    <description>Presence of anti-drug (ACE-536/Luspatercept) antibodies was assessed every 24 weeks from serum samples.&#xD;
A participant is counted as 'positive' if there is any positive result captured during the study. A participant is counted as 'negative' if there is no positive result captured during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Apparent Clearance (CL/F) of Luspatercept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Time to Reach Maximum Concentration (Tmax) of Luspatercept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Maximum Concentration (Cmax) of Luspatercept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Steady State (AUCss) of Luspatercept</measure>
    <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
    <description>Area Under the Curve From Steady State (AUCss) of Luspatercept</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Luspatercept (ACE-536) plus Best Supportive Care (BSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Best Supportive Care (BSC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline solution subcutaneous(ly) (SC) once every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luspatercept</intervention_name>
    <description>Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.</description>
    <arm_group_label>Luspatercept (ACE-536) plus Best Supportive Care (BSC)</arm_group_label>
    <other_name>ACE-536</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, Subcutaneous, every 21 days</description>
    <arm_group_label>Placebo plus Best Supportive Care (BSC)</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care (BSC)</intervention_name>
    <description>Best Supportive Care (BSC)</description>
    <arm_group_label>Luspatercept (ACE-536) plus Best Supportive Care (BSC)</arm_group_label>
    <arm_group_label>Placebo plus Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Subjects must be ≥ 18 years of age at the time of signing the informed consent&#xD;
             document (ICF).&#xD;
&#xD;
          2. Subject must understand and voluntarily sign an ICF prior to any study-related&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          3. Subject is willing and able to adhere to the study visit schedule (eg, not scheduled&#xD;
             to receive hematopoietic stem cell transplantation) and other protocol requirements.&#xD;
&#xD;
          4. Subject must have documented diagnosis of β-thalassemia or hemoglobin E/&#xD;
             β-thalassemia. Concomitant alpha globin mutation and/or duplication are allowed.&#xD;
&#xD;
          5. Subject must be non-transfusion dependent, defined as 0 to 5 units of RBCs received&#xD;
             during the 24-week period prior to randomization. Note: 1 unit defined for this entry&#xD;
             criterion as approximately 200 to 350 mL of transfused packed RBCs.&#xD;
&#xD;
          6. Subject must not be on a regular transfusion program and must be RBC transfusion-free&#xD;
             for at least ≥ 8 weeks prior to randomization&#xD;
&#xD;
          7. Subject must have mean baseline hemoglobin ≤ 10 g/dL, based on a minimum of 2&#xD;
             measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values&#xD;
             within 21 days post-transfusion will be excluded.&#xD;
&#xD;
          8. Subject must have performance status: Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance score of 0 to 1.&#xD;
&#xD;
          9. A female of childbearing potential (FCBP) for this study is defined as a female who:&#xD;
&#xD;
        1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral&#xD;
        oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer&#xD;
        therapy does not rule out childbearing potential) for at least 24 consecutive months (ie,&#xD;
        has had menses at any time in the preceding 24 consecutive months). A FCBP participating in&#xD;
        the study must:&#xD;
&#xD;
          1. Have 2 negative pregnancy tests as verified by the Investigator prior to starting&#xD;
             study therapy. She must agree to ongoing pregnancy testing during the course of the&#xD;
             study, and after end of study treatment. This applies even if the subject practices&#xD;
             true abstinence* from heterosexual contact.&#xD;
&#xD;
          2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on&#xD;
             a monthly basis and source documented). If a FCBP engages in sexual activity that may&#xD;
             result in a pregnancy, she must agree to use, and be able to comply during the study&#xD;
             therapy (including dose interruptions), and for 12 weeks (approximately 5 times the&#xD;
             mean terminal half-life of luspatercept based on multiple dose pharmacokinetics [PK]&#xD;
             data) after discontinuation of study therapy.&#xD;
&#xD;
             10. Male subjects must:&#xD;
&#xD;
        a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a&#xD;
        condom during sexual contact with a pregnant female or a female of childbearing potential&#xD;
        while participating in the study, during dose interruptions and for at least 12 weeks&#xD;
        (approximately 5 times the mean terminal half-life of luspatercept based on multiple-dose&#xD;
        PK data) following IP discontinuation, even if he has undergone a successful vasectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
          1. Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from participating in the study.&#xD;
&#xD;
          2. Any condition including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
          3. Any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
          4. Diagnosis of hemoglobin S/β-thalassemia or alpha (α)-thalassemia (eg,Hemoglobin H).&#xD;
&#xD;
          5. Active hepatitis C (HCV) infection&#xD;
&#xD;
          6. Deep vein thrombosis (DVT) or stroke requiring medical intervention ≤ 24 weeks prior&#xD;
             to randomization.&#xD;
&#xD;
          7. Subjects on chronic anticoagulant therapy are excluded, unless they stopped the&#xD;
             treatment at least 28 days prior to randomization. Anticoagulant therapies for&#xD;
             prophylaxis and for surgery or high-risk procedures as well as low molecular weight&#xD;
             (LMW) heparin for superficial vein thrombosis (SVT) and chronic aspirin are allowed&#xD;
             before and during the study.&#xD;
&#xD;
          8. Treatment with another investigational drug or device ≤ 28 days prior to&#xD;
             randomization.&#xD;
&#xD;
          9. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536).&#xD;
&#xD;
         10. Platelet count &gt; 1000 x 109/L.&#xD;
&#xD;
         11. Subjects on iron chelation therapy (ICT) at the time of ICF signature must have&#xD;
             initiated the treatment with ICT at least 24 weeks before the predicted randomization&#xD;
             date. ICT can be initiated at any time during treatment and should be used according&#xD;
             to the label.&#xD;
&#xD;
         12. Subject had Hydroxyurea and ESA treatment ≤ 24 weeks prior to randomization, and no&#xD;
             prior gene therapy.&#xD;
&#xD;
         13. Subject is pregnant or a lactating female.&#xD;
&#xD;
         14. Uncontrolled hypertension. Controlled hypertension for this protocol is considered ≤&#xD;
             Grade 1 according to National Cancer Institute Common Terminology for Adverse Events&#xD;
             (NCI CTCAE) version 4.0 (current active minor version).&#xD;
&#xD;
         15. Subject has major organ damage, including:&#xD;
&#xD;
               1. Liver disease with alanine aminotransferase (ALT) &gt; 3 x upper limit of normal&#xD;
                  (ULN) or history/evidence of cirrhosis, as well as presence of masses/tumor&#xD;
                  detected by ultrasound at screening.&#xD;
&#xD;
               2. Heart disease, heart failure as classified by the New York Heart Association&#xD;
                  (NYHA) classification 3 or higher, or significant arrhythmia requiring treatment,&#xD;
                  or recent myocardial infarction (MI) within 6 months of randomization.&#xD;
&#xD;
               3. Severe lung disease, including pulmonary fibrosis or pulmonary hypertension, ie,&#xD;
                  ≥G3 NCI CTCAE version 4.0 (current active minor version).&#xD;
&#xD;
               4. Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m2 (per Modification&#xD;
                  of Diet in Renal Disease [MDRD] formula).&#xD;
&#xD;
         16. Subject has received chronic systemic glucocorticoids ≤ 12 weeks prior to&#xD;
             randomization (physiologic replacement therapy for adrenal insufficiency is allowed).&#xD;
&#xD;
         17. Major surgery ≤ 12 weeks prior to randomization (subjects must have completely&#xD;
             recovered from any previous surgery prior to randomization).&#xD;
&#xD;
         18. History of severe allergic or anaphylactic reactions or hypersensitivity to&#xD;
             recombinant proteins or excipients in the investigational product (see Investigator&#xD;
             Brochure).&#xD;
&#xD;
         19. Subject has received immunosuppressants ≤ 28 days prior to randomization.&#xD;
&#xD;
         20. History or current malignancies (solid tumors and hematological malignancies) unless&#xD;
             the subject has been free of the disease (including completion of any active or&#xD;
             adjuvant treatment for prior malignancy) for ≥ 5 years. However, subjects with the&#xD;
             following history/concurrent conditions are allowed:&#xD;
&#xD;
               -  Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Carcinoma in situ of the breast&#xD;
&#xD;
               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,&#xD;
                  nodes, metastasis [TNM] clinical staging system)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeevan Shetty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aghia Sofia Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Cagliari - ASL8</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite</name>
      <address>
        <city>Genoa</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca Granda IRCCS Ospedale Maggiore</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita Degli Studi Di Napoli</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN A Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chronic Care Center</name>
      <address>
        <city>Hazmieh</city>
        <zip>1003</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London Bloomsbury</city>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.</citation>
    <PMID>30617198</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>September 10, 2021</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>(β)-Thalassemia</keyword>
  <keyword>Beta-Thalassemia</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Luspatercept</keyword>
  <keyword>ACE-536</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Placebo</keyword>
  <keyword>Red Blood Cell Transfusions</keyword>
  <keyword>Erythrocyte transfusion</keyword>
  <keyword>Hb increase</keyword>
  <keyword>NTDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Luspatercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03342404/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03342404/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>145 participants were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Luspatercept</title>
          <description>Luspatercept SC 1mg/Kg Q3W</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride SC Q3W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Luspatercept</title>
          <description>Luspatercept SC 1mg/Kg Q3W</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride SC Q3W</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="13.24"/>
                    <measurement group_id="B2" value="41.1" spread="11.90"/>
                    <measurement group_id="B3" value="39.9" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Erythroid Response (Week 13 to Week 24)</title>
        <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 13 to 24 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
        <time_frame>From Week 13 to Week 24 of study treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Erythroid Response (Week 13 to Week 24)</title>
          <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 13 to 24 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="67.4" upper_limit="85.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The Estimated Odds Ratio (OR) is Infinite (INF)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in proportions</param_type>
            <param_value>77.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.4</ci_lower_limit>
            <ci_upper_limit>87.0</ci_upper_limit>
            <estimate_desc>The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>77.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.7</ci_lower_limit>
            <ci_upper_limit>85.5</ci_upper_limit>
            <estimate_desc>The common risk difference (luspatercept - placebo) and 95% CI were estimated from the CMH test stratified by baseline Hb category and baseline NTDT-PRO T/W domain score category</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 13 to Week 24)</title>
        <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the T/W Domain Score at baseline.</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and from Week 13 to Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 13 to Week 24)</title>
          <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the T/W Domain Score at baseline.</description>
          <population>All treated participants with available measurements at Baseline and from Week 13 to Week 24</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="1.862"/>
                    <measurement group_id="O2" value="-0.47" spread="1.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 13 to Week 24)</title>
        <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
        <time_frame>From Week 13 to Week 24 of study treatment (over a continuous 12-week interval)</time_frame>
        <population>All treated participants with available measurements at Baseline and From Week 13 to Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 13 to Week 24)</title>
          <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
          <population>All treated participants with available measurements at Baseline and From Week 13 to Week 24</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.820"/>
                    <measurement group_id="O2" value="0.13" spread="0.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Erythroid Response (Week 37 to Week 48)</title>
        <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 37 to 48 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
        <time_frame>From Week 37 to Week 48 of study treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Erythroid Response (Week 37 to Week 48)</title>
          <description>Erythroid Response is defined as an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Weeks 37 to 48 of treatment in the absence of transfusions.&#xD;
Baseline hemoglobin (Hb) is the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1.</description>
          <population>All treated participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="60.7" upper_limit="79.7"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</title>
        <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 13 to Week 24 is compared to the FS score at baseline (last score available before start of study treatment).</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</title>
          <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 13 to Week 24 is compared to the FS score at baseline (last score available before start of study treatment).</description>
          <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="7.937"/>
                    <measurement group_id="O2" value="0.31" spread="5.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 13 to Week 24)</title>
        <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the SoB Domain Score at baseline.</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 13 to Week 24 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and From Week 13 to Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 13 to Week 24)</title>
          <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 13 to Week 24) are compared to the SoB Domain Score at baseline.</description>
          <population>All treated participants with available measurements at Baseline and From Week 13 to Week 24</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="1.693"/>
                    <measurement group_id="O2" value="-0.18" spread="1.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 37 to Week 48)</title>
        <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
        <time_frame>From Week 37 to Week 48 of study treatment (over a continuous 12-week interval)</time_frame>
        <population>All treated participants with available measurements at Baseline and From Week 37 to Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hemoglobin Values in the Absence of Transfusion (Week 37 to Week 48)</title>
          <description>Mean change from baseline in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
          <population>All treated participants with available measurements at Baseline and From Week 37 to Week 48</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.812"/>
                    <measurement group_id="O2" value="0.07" spread="0.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</title>
        <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 37 to Week 48 is compared to the FS score at baseline (last score available before start of study treatment).</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</title>
          <description>The FACIT-F is a multidimensional, self-report quality of life instrument which includes the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire (27 items over 4 different domains), and the Fatigue subscale (FS) component (13 items). FACIT-F version 4 has been used for this study.&#xD;
For the Fatigue subscale, each of the 13 items is scored from 0 (&quot;not at all&quot;) to 4 (&quot;very much&quot;).&#xD;
The scores from individual items are summed to generated the final FS score, which ranges from 0 (best outcome) to 52 (worst outcome).&#xD;
The questionnaire is completed every other dose, and the mean of FS scores from Week 37 to Week 48 is compared to the FS score at baseline (last score available before start of study treatment).</description>
          <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="7.785"/>
                    <measurement group_id="O2" value="0.09" spread="5.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 37 to Week 48)</title>
        <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the T/W Domain Score at baseline.</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at Week 37 to Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score (Week 37 to Week 48)</title>
          <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Tiredness/Weakness (T/W) domain score represents the average score of items 1 through 4 above. T/W domain score ranges from 0 (best outcome, no tiredness/weakness) to 10 (worst outcome, extreme tiredness/weakness). Weekly T/W Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the T/W Domain Score at baseline.</description>
          <population>All treated participants with available measurements at Baseline and at Week 37 to Week 48</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="2.117"/>
                    <measurement group_id="O2" value="-0.16" spread="1.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 37 to Week 48)</title>
        <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the SoB Domain Score at baseline.</description>
        <time_frame>Baseline (up to 7 days prior to start of study treatment) and from Week 37 to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and From Week 37 to Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Shortness of Breath (SoB) Domain Score (Week 37 to Week 48)</title>
          <description>The NTDT-PRO V2.1 assess the severity of anemia-related symptoms associated with NTD β-thalassemia. It is a daily electronic diary with recall of symptoms during the past 24 hours, composed of 6 items:&#xD;
Tiredness (lack of energy) when not doing physical activity&#xD;
Tiredness (lack of energy) when doing physical activity&#xD;
Weakness (lack of strength) when not doing physical activity&#xD;
Weakness (lack of strength) when doing physical activity&#xD;
Shortness of breath when not doing physical activity&#xD;
Shortness of breath when doing physical activity. The Shortness of Breath (SoB) domain score represents the average score of items 5 and 6 above. SoB domain score ranges from 0 (best outcome, no shortness of breath) to 10 (worst outcome, extreme shortness of breath). Weekly SoB Scores represent the average of daily scores for that week. The mean of weekly scores over a continuous 12 week period (from Week 37 to Week 48) are compared to the SoB Domain Score at baseline.</description>
          <population>All treated participants with available measurements at Baseline and From Week 37 to Week 48</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="1.851"/>
                    <measurement group_id="O2" value="0.29" spread="1.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</title>
        <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
        <time_frame>From Week 13 to Week 24 of study treatment (over a continuous 12-week interval)</time_frame>
        <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 13 to Week 24)</title>
          <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
          <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="30.4" upper_limit="51.0"/>
                    <measurement group_id="O2" value="27.7" lower_limit="15.6" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</title>
        <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
        <time_frame>From Week 37 to Week 48 of study treatment (over a continuous 12-week interval)</time_frame>
        <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase From Baseline ≥ 3 in Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score (Week 37 to Week 48)</title>
          <description>The FACIT-Fatigue, is a multidimensional, self-report quality of life instrument. It consists of 27 core items, the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, which assesses patient function in 4 domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale (FS). The items are measured on a response scale with five options (0 = not at all to 4 = very much).&#xD;
Participants completed the questionnaire at screening and every other dose.</description>
          <population>All treated participants with available measurements at Baseline and at least one post-baseline FACIT-F questionnaire completed</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="26.5" upper_limit="46.7"/>
                    <measurement group_id="O2" value="21.3" lower_limit="10.7" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of the Medical Outcomes Study 36-Item Short Form (SF-36)</title>
        <description>The SF-36v2 is a 36-item generic PRO questionnaire used to assess patient-reported outcomes. The SF-36 yields scores for 8 domains of health: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH) as well as physical component summary (PCS) and mental component summary (MCS) scores.&#xD;
Scores from each of the 8 domains of health are first normalized based on US general population means, then aggregated and transformed (according to specific standardization formulas detailed in the Statistical Protocol Analysis), so that the scores from each of the 8 domains of health will contribute differently to the determination of PCS and MCS summary scores.&#xD;
PCS and MCS scores range from 0 to 100, with higher scores indicating a better quality of life.</description>
        <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline, at Week 24 and at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of the Medical Outcomes Study 36-Item Short Form (SF-36)</title>
          <description>The SF-36v2 is a 36-item generic PRO questionnaire used to assess patient-reported outcomes. The SF-36 yields scores for 8 domains of health: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH) as well as physical component summary (PCS) and mental component summary (MCS) scores.&#xD;
Scores from each of the 8 domains of health are first normalized based on US general population means, then aggregated and transformed (according to specific standardization formulas detailed in the Statistical Protocol Analysis), so that the scores from each of the 8 domains of health will contribute differently to the determination of PCS and MCS summary scores.&#xD;
PCS and MCS scores range from 0 to 100, with higher scores indicating a better quality of life.</description>
          <population>All treated participants with available measurements at Baseline, at Week 24 and at Week 48</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary (PCS) at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="7.149"/>
                    <measurement group_id="O2" value="-1.18" spread="5.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Summary (PCS) at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="5.277"/>
                    <measurement group_id="O2" value="0.48" spread="5.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary (MCS) at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="8.816"/>
                    <measurement group_id="O2" value="-0.76" spread="6.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary (MCS) at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="7.882"/>
                    <measurement group_id="O2" value="-2.53" spread="6.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement of Iron Overload</title>
        <description>Iron overload was measured by Liver Iron Concentration (LIC) and Iron Chelation Therapy (ICT) daily dose.&#xD;
Improvement is defined as:&#xD;
For participants with baseline LIC ≥3 mg/g: ≥20% reduction in LIC or ≥ 33% decrease in ICT daily dose&#xD;
For participants with baseline LIC &lt;3 mg/g: no increase in LIC &gt;1 mg/g and not starting treatment with ICT, or no increase in ICT daily dose ≥ 33% (if on ICT at baseline)</description>
        <time_frame>Week 24 and Week 48 of study treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement of Iron Overload</title>
          <description>Iron overload was measured by Liver Iron Concentration (LIC) and Iron Chelation Therapy (ICT) daily dose.&#xD;
Improvement is defined as:&#xD;
For participants with baseline LIC ≥3 mg/g: ≥20% reduction in LIC or ≥ 33% decrease in ICT daily dose&#xD;
For participants with baseline LIC &lt;3 mg/g: no increase in LIC &gt;1 mg/g and not starting treatment with ICT, or no increase in ICT daily dose ≥ 33% (if on ICT at baseline)</description>
          <population>All treated participants</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Serum Ferritin</title>
        <description>Baseline mean serum ferritin is calculated during the 24 weeks on or prior to dose 1 day 1. Post-baseline mean serum ferritin is calculated as mean of ferritin values during the last 24 weeks on or prior to the end date of the first 24 week or 48 week treatment</description>
        <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at week 24 or week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Serum Ferritin</title>
          <description>Baseline mean serum ferritin is calculated during the 24 weeks on or prior to dose 1 day 1. Post-baseline mean serum ferritin is calculated as mean of ferritin values during the last 24 weeks on or prior to the end date of the first 24 week or 48 week treatment</description>
          <population>All treated participants with available measurements at Baseline and at week 24 or week 48</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.32" spread="249.820"/>
                    <measurement group_id="O2" value="0.90" spread="98.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.21" spread="236.406"/>
                    <measurement group_id="O2" value="58.26" spread="211.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Liver Iron Concentration (LIC)</title>
        <description>LIC was measured by Magnetic Resonance Imaging (MRI). Baseline is defined as the last value on or before the first dose of study drug is administered; Postbaseline is defined as the closest visit at Week 24 or Week 48.&#xD;
Participants with LIC value &gt;43 are not included in the analysis.</description>
        <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at week 24 or week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Liver Iron Concentration (LIC)</title>
          <description>LIC was measured by Magnetic Resonance Imaging (MRI). Baseline is defined as the last value on or before the first dose of study drug is administered; Postbaseline is defined as the closest visit at Week 24 or Week 48.&#xD;
Participants with LIC value &gt;43 are not included in the analysis.</description>
          <population>All treated participants with available measurements at Baseline and at week 24 or week 48</population>
          <units>mg/g dry weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.930"/>
                    <measurement group_id="O2" value="-0.18" spread="1.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="1.540"/>
                    <measurement group_id="O2" value="-0.91" spread="2.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Transfusion-Free Over 24 Weeks</title>
        <description>Transfusion free is defined as the absence of any transfusion during Week 1-24 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 24 were not considered as transfusion free during Week 1-24.</description>
        <time_frame>From start of treatment to 24 weeks following start of treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Transfusion-Free Over 24 Weeks</title>
          <description>Transfusion free is defined as the absence of any transfusion during Week 1-24 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 24 were not considered as transfusion free during Week 1-24.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Transfusion-Free Over 48 Weeks</title>
        <description>Transfusion free is defined as the absence of any transfusion during Week 1-48 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 48 were not considered as transfusion free during Week 1-48.</description>
        <time_frame>From start of treatment to 48 weeks following start of treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Transfusion-Free Over 48 Weeks</title>
          <description>Transfusion free is defined as the absence of any transfusion during Week 1-48 of study treatment.&#xD;
Participants who discontinued treatment prior to Week 48 were not considered as transfusion free during Week 1-48.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3"/>
                    <measurement group_id="O2" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of the Mean Hemoglobin Increase From Baseline ≥1.0 g/dL</title>
        <description>The duration of increase is defined as Last Day of mean hemoglobin increase by &gt;=1.0g/dL - First Day of increase +1.</description>
        <time_frame>From first to last Hemoglobin measurement with increase from baseline ≥1.0 g/dL (up to approximately 20 months)</time_frame>
        <population>All participants with a mean hemoglobin increase ≥1.0 g/dL</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of the Mean Hemoglobin Increase From Baseline ≥1.0 g/dL</title>
          <description>The duration of increase is defined as Last Day of mean hemoglobin increase by &gt;=1.0g/dL - First Day of increase +1.</description>
          <population>All participants with a mean hemoglobin increase ≥1.0 g/dL</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611.7" spread="243.29"/>
                    <measurement group_id="O2" value="176.5" spread="132.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the 6-Minute Walk Test (6MWT) Distance</title>
        <description>The 6MWT is typically used to objectively assess functional exercise capacity and response to medical interventions in patients with various moderate to severe diseases. Subjects are asked to walk as quickly as possible without running along a 30-meter corridor for six minutes, and the total distance covered during that time is measured.&#xD;
Baseline is defined as the last value on or before the first dose of study drug is administered. Postbaseline is defined as the closest visit at Week 24 or Week 48.</description>
        <time_frame>From baseline to Week 24 and from baseline to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at Week 24 or Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the 6-Minute Walk Test (6MWT) Distance</title>
          <description>The 6MWT is typically used to objectively assess functional exercise capacity and response to medical interventions in patients with various moderate to severe diseases. Subjects are asked to walk as quickly as possible without running along a 30-meter corridor for six minutes, and the total distance covered during that time is measured.&#xD;
Baseline is defined as the last value on or before the first dose of study drug is administered. Postbaseline is defined as the closest visit at Week 24 or Week 48.</description>
          <population>All treated participants with available measurements at Baseline and at Week 24 or Week 48</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.44" spread="58.748"/>
                    <measurement group_id="O2" value="-3.36" spread="85.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread="63.281"/>
                    <measurement group_id="O2" value="0.87" spread="52.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase From Baseline ≥1.5 g/dL in Mean Hemoglobin Values in the Absence of Transfusion</title>
        <description>Percentage of participants who have an increase from baseline ≥1.5 g/dL in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
        <time_frame>From Week 13 to Week 24 of study treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase From Baseline ≥1.5 g/dL in Mean Hemoglobin Values in the Absence of Transfusion</title>
          <description>Percentage of participants who have an increase from baseline ≥1.5 g/dL in mean of hemoglobin (Hb) values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions.&#xD;
Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.</description>
          <population>All treated participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="41.6" upper_limit="62.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease From Baseline ≥ RD (= 1) in the Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score</title>
        <description>The RD for the NTDT-PRO T/W domain score was defined as ≥ 1-point decrease (ie, RD = -1) from baseline over the time from Week 13 to Week 24 or from Week 37 to Week 48.&#xD;
Subjects with missing NTDT-PRO T/W scores at the indicated 12-week period are classified as non-responders in the analysis.</description>
        <time_frame>From Week 13 to Week 24 and from Week 37 to Week 48 of study treatment</time_frame>
        <population>All treated participants with available measurements at Baseline and at the indicated 12-week periods</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease From Baseline ≥ RD (= 1) in the Non-Transfusion Dependent β-thalassemia-Patient Reported Outcome (NTDT-PRO) Tiredness and Weakness (T/W) Domain Score</title>
          <description>The RD for the NTDT-PRO T/W domain score was defined as ≥ 1-point decrease (ie, RD = -1) from baseline over the time from Week 13 to Week 24 or from Week 37 to Week 48.&#xD;
Subjects with missing NTDT-PRO T/W scores at the indicated 12-week period are classified as non-responders in the analysis.</description>
          <population>All treated participants with available measurements at Baseline and at the indicated 12-week periods</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13 to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="27.8" upper_limit="48.0"/>
                    <measurement group_id="O2" value="28.6" lower_limit="16.6" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37 to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="22.2" upper_limit="41.5"/>
                    <measurement group_id="O2" value="18.4" lower_limit="8.8" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>Number of participants experiencing different types (any grade) of adverse events</description>
        <time_frame>From first dose to 63 days after last dose (up to approximately 50 months)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>Number of participants experiencing different types (any grade) of adverse events</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent adverse-event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Dose Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Dose Delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE Leading to Dose Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE Leading to Dose Delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-drug Antibody (ADA) Positive Test for Luspatercept</title>
        <description>Presence of anti-drug (ACE-536/Luspatercept) antibodies was assessed every 24 weeks from serum samples.&#xD;
A participant is counted as 'positive' if there is any positive result captured during the study. A participant is counted as 'negative' if there is no positive result captured during the study.</description>
        <time_frame>From first dose and up to 2 years following last dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride SC Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibody (ADA) Positive Test for Luspatercept</title>
          <description>Presence of anti-drug (ACE-536/Luspatercept) antibodies was assessed every 24 weeks from serum samples.&#xD;
A participant is counted as 'positive' if there is any positive result captured during the study. A participant is counted as 'negative' if there is no positive result captured during the study.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) of Luspatercept</title>
        <description>Apparent Clearance (CL/F) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of Luspatercept</title>
          <description>Apparent Clearance (CL/F) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>L/day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.458" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</title>
        <description>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</title>
          <description>Apparent Volume of Distribution of the Central Compartment (V1/F) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) of Luspatercept</title>
        <description>Time to Reach Maximum Concentration (Tmax) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) of Luspatercept</title>
          <description>Time to Reach Maximum Concentration (Tmax) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" lower_limit="4.33" upper_limit="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Luspatercept</title>
        <description>Maximum Concentration (Cmax) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Luspatercept</title>
          <description>Maximum Concentration (Cmax) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</title>
        <description>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</title>
          <description>Maximum Concentration From Steady State (Cmax,ss) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Steady State (AUCss) of Luspatercept</title>
        <description>Area Under the Curve From Steady State (AUCss) of Luspatercept</description>
        <time_frame>At predose (Dose 1 Day 1, before the first dose), Dose 2 Day 1, Dose 4 Day 1, Dose 6 Day 1, Dose 6 Day 8, Dose 6 Day 15, Dose 8 Day 1, Dose 12 Day 1, Dose 16 Day 1 (up to approximately 48 months)</time_frame>
        <population>All treated participants receiving the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Luspatercept</title>
            <description>Luspatercept SC 1mg/Kg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Steady State (AUCss) of Luspatercept</title>
          <description>Area Under the Curve From Steady State (AUCss) of Luspatercept</description>
          <population>All treated participants receiving the study drug</population>
          <units>day*μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 63 days after last dose (up to approximately 50 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Luspatercept</title>
          <description>Luspatercept SC 1mg/Kg Q3W</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride SC Q3W</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Extramedullary haemopoiesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dengue haemorrhagic fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Extramedullary haemopoiesis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Prehypertension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

